Cargando…

Attenuation of diabetic kidney injury in DPP4-deficient rats; role of GLP-1 on the suppression of AGE formation by inducing glyoxalase 1

Dipeptidyl peptidase 4 (DPP4) inactivates incretin hormone glucagon-like peptide-1. DPP4 inhibitors may exert beneficial effects on diabetic nephropathy (DN) independently of glycemic control; however, the mechanisms underlying are not fully understood. Here, we investigated the mechanisms of the be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sarker, Mithun Kumer, Lee, Jong Han, Lee, Dae Ho, Chun, Kwang-Hoon, Jun, Hee-Sook
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6977656/ https://www.ncbi.nlm.nih.gov/pubmed/31905169 http://dx.doi.org/10.18632/aging.102643

Ejemplares similares

DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
por: Razavi, Michael, et al.
Publicado: (2022)

2-Iodo-4′-Methoxychalcone Attenuates Methylglyoxal-Induced Neurotoxicity by Activation of GLP-1 Receptor and Enhancement of Neurotrophic Signal, Antioxidant Defense and Glyoxalase Pathway
por: Tseng, Yu-Ting, et al.
Publicado: (2019)

Emerging Glycation-Based Therapeutics—Glyoxalase 1 Inducers and Glyoxalase 1 Inhibitors
por: Rabbani, Naila, et al.
Publicado: (2022)

A genetic variant in GLP1R is associated with response to DPP-4 inhibitors in patients with type 2 diabetes
por: Han, Eugene, et al.
Publicado: (2016)

Glyoxalase 1 as a Therapeutic Target in Cancer and Cancer Stem Cells
por: Kim, Ji-Young, et al.
Publicado: (2022)

Mild Oxidative Damage in the Diabetic Rat Heart Is Attenuated by Glyoxalase-1 Overexpression
por: Brouwers, Olaf, et al.
Publicado: (2013)

Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective
por: Brown, Dominique Xavier, et al.
Publicado: (2012)

The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system
por: Schernthaner, Guntram, et al.
Publicado: (2014)

Increased Glyoxalase-1 Levels in Fkbp5 Knockout Mice Caused by Glyoxalase-1 Gene Duplication
por: Kollmannsberger, Lorenz K., et al.
Publicado: (2013)

Anti-hyperglycemic activity of myricetin, through inhibition of DPP-4 and enhanced GLP-1 levels, is attenuated by co-ingestion with lectin-rich protein
por: Lalitha, Nanjaiah, et al.
Publicado: (2020)

From Theory to Clinical Practice in the Use of GLP-1 Receptor Agonists and DPP-4 Inhibitors Therapy
por: Dicembrini, Ilaria, et al.
Publicado: (2011)

Therapeutic stimulation of GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment
por: Sharma, Alok, et al.
Publicado: (2015)

The effect of DPP-4-protected GLP-1 (7–36) on coronary microvascular function in obese adults
por: Nilsson, Malin, et al.
Publicado: (2019)

Glyoxalase Goes Green: The Expanding Roles of Glyoxalase in Plants
por: Sankaranarayanan, Subramanian, et al.
Publicado: (2017)

Glucolipotoxicity and GLP-1 secretion
por: Hong, Jung-Hee, et al.
Publicado: (2021)

SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review
por: El Mouhayyar, Christopher, et al.
Publicado: (2020)

Dihydromyricetin Enhances Exercise-Induced GLP-1 Elevation through Stimulating cAMP and Inhibiting DPP-4
por: Wu, Luting, et al.
Publicado: (2022)

Inhibition of DPP-IV Activity and Stimulation of GLP-1 Release by Gastrointestinally Digested Black Soldier Fly Prepupae
por: Luparelli, Anna Valentina, et al.
Publicado: (2023)

Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control
por: Stenlid, Rasmus, et al.
Publicado: (2023)

GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer’s Disease Therapy
por: Złotek, Magdalena, et al.
Publicado: (2023)

A potential therapeutic combination for treatment of COVID-19: Synergistic effect of DPP4 and RAAS suppression
por: Phyu Khin, Phyu, et al.
Publicado: (2020)

Retraction Note: therapeutic stimulation of GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment
por: Sharma, Alok, et al.
Publicado: (2016)

Influence of Diet and Gender on Plasma DPP4 Activity and GLP-1 in Patients with Metabolic Syndrome: An Experimental Pilot Study
por: Pérez-Durillo, Francisco Tomás, et al.
Publicado: (2018)

DPP-4 inhibition enhanced renal tubular and myocardial GLP-1 receptor expression decreased in CKD with myocardial infarction
por: Kim, Seung Jung, et al.
Publicado: (2019)

GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials
por: Gilbert, Matthew P., et al.
Publicado: (2020)

Targeting cellular senescence prevents glucocorticoid-induced bone loss through modulation of the DPP4-GLP-1 axis
por: Wang, Tiantian, et al.
Publicado: (2021)

Glyoxalases in Urological Malignancies
por: Antognelli, Cinzia, et al.
Publicado: (2018)

Temporal Dynamics of Glyoxalase 1 in Secondary Neuronal Injury
por: Pieroh, Philipp, et al.
Publicado: (2014)

Methylglyoxal-Glyoxalase 1 Balance: The Root of Vascular Damage
por: Nigro, Cecilia, et al.
Publicado: (2017)

AGEs and neurodegeneration: the Nrf2/glyoxalase-1 interaction
por: Mastrocola, Raffaella
Publicado: (2016)

Strong Association Between Weight Reduction and Suppression of Cardiovascular Events in Recent Clinical Trials of DPP4 Inhibitors, GLP-1 Receptor Agonists, and SGLT2 Inhibitors
por: Yanagawa, Tatsuo
Publicado: (2018)

Attenuated Postprandial GLP-1 Response in Parkinson’s Disease
por: Manfready, Richard A., et al.
Publicado: (2021)

Dissecting the Physiological Function of Plant Glyoxalase I and Glyoxalase I-Like Proteins
por: Schmitz, Jessica, et al.
Publicado: (2018)

Glyoxalase 2: Towards a Broader View of the Second Player of the Glyoxalase System
por: Scirè, Andrea, et al.
Publicado: (2022)

Kinetic evidence in favor of glyoxalase III and against deglycase activity of DJ‐1
por: Choi, Joonhyeok, et al.
Publicado: (2023)

Candesartan Attenuates Diabetic Retinal Vascular Pathology by Restoring Glyoxalase-I Function
por: Miller, Antonia G., et al.
Publicado: (2010)

The Effects of Aerobic Exercises and 25(OH) D Supplementation on GLP1 and DPP4 Level in Type II Diabetic Patients
por: Rahimi, Naser, et al.
Publicado: (2017)

DPP4 gene variation affects GLP-1 secretion, insulin secretion, and glucose tolerance in humans with high body adiposity
por: Böhm, Anja, et al.
Publicado: (2017)

A Physiologically‐Based Quantitative Systems Pharmacology Model of the Incretin Hormones GLP‐1 and GIP and the DPP4 Inhibitor Sitagliptin
por: Balazki, Pavel, et al.
Publicado: (2020)

Effects of Sambiloto (Andrographis paniculata) on GLP-1 and DPP-4 Concentrations between Normal and Prediabetic Subjects: A Crossover Study
por: Tarigan, Tri Juli Edi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s7qbhvf77cbqeacmniiqfkmdgn